Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Lloyd B. Klickstein"'
Autor:
Christoph Schramm, Heiner Wedemeyer, Andrew Mason, Gideon M. Hirschfield, Cynthia Levy, Kris V. Kowdley, Piotr Milkiewicz, Ewa Janczewska, Elena Sergeevna Malova, Johanne Sanni, Phillip Koo, Jin Chen, Subhajit Choudhury, Lloyd B. Klickstein, Michael K. Badman, David Jones
Publikováno v:
JHEP Reports, Vol 4, Iss 11, Pp 100544- (2022)
Background & Aims: The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind, placebo-controlled study as potential second-line therapy for patients with primary bil
Externí odkaz:
https://doaj.org/article/3923e32517ec458db31731c6b79c2204
Autor:
Eloy D. Hernandez, Lianxing Zheng, Young Kim, Bin Fang, Bo Liu, Reginald A. Valdez, William F. Dietrich, Paul V. Rucker, Donatella Chianelli, James Schmeits, Dingjiu Bao, Jocelyn Zoll, Claire Dubois, Glenn C. Federe, Lihao Chen, Sean B. Joseph, Lloyd B. Klickstein, John Walker, Valentina Molteni, Peter McNamara, Shelly Meeusen, David C. Tully, Michael K. Badman, Jie Xu, Bryan Laffitte
Publikováno v:
Hepatology Communications, Vol 3, Iss 8, Pp 1085-1097 (2019)
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients
Externí odkaz:
https://doaj.org/article/f910e104a218414a82b33320fcf44859
Autor:
Diana J. Leeming, Jannie M. Sand, Mette J. Nielsen, Federica Genovese, Fernando J. Martinez, Cory M. Hogaboam, MeiLan K Han, Lloyd B. Klickstein, Morten A. Karsdal
Publikováno v:
Biomarker Insights, Vol 2012, Iss 7, Pp 119-126 (2012)
Externí odkaz:
https://doaj.org/article/2539505e9f76453897e3df99843b95e1
Autor:
Rowan, Stringer, Jin, Chen, Bharti, Shah, Jessie, Gu, Yiming, Zhang, William, Prince, Lloyd B, Klickstein, Ralph, Woessner
Publikováno v:
Clinical Pharmacology in Drug Development. 12:122-131
This open-label, randomized, 3-treatment, 3-period, 6-sequence, crossover study in healthy subjects compared the pharmacokinetic and pharmacodynamic properties of a lipid-based (soft gelatin capsule) prototype final market image (pFMI) formulation of
Autor:
Lu Gan, Kate Danis, Lloyd B. Klickstein, Jin Chen, Sachin Desai, Soniya Vaidya, Michael Badman, Bryan A. Laffitte, Srikanth Neelakantham, Jie Zhang
Publikováno v:
Clinical Pharmacology in Drug Development
Tropifexor (LJN452) is a potent, orally available, non–bile acid farnesoid X receptor agonist under clinical development for chronic liver diseases. Here, we present results from a first‐in‐human study of tropifexor following single‐ and mult
Autor:
Lloyd B. Klickstein
Publikováno v:
Current protocols in molecular biologyLiterature Cited. 4(1)
Autor:
Jinhai Gao, Andreas Harsch, Dong Liu, Deborah Rothman, Stephen M. Canham, Silvio Roggo, Joseph Loureiro, John A. Tallarico, Philipp Krastel, Lloyd B. Klickstein, Gregory A. Michaud, Christy Fryer, Bushell Simon, Savage Nik, Michael Salcius, Kian L. Tan, Joerg Kallen, Feng Cong, Philipp Lustenberger, Manuel Mihalic, Eric T Williams, Aude Izaac, Jian Ding, Patrick J. Devine, Xiaobo Xia, Fred Harbinski, Erhan I. Altinoglu, Shaowen Wang, Rishi K. Jain, Liling Zeng, Xiaolin Gao, Larraufie Marie-Helene
Publikováno v:
Cell chemical biology. 28(9)
Summary Acute kidney injury (AKI) is a life-threatening disease with no known curative or preventive therapies. Data from multiple animal models and human studies have linked dysregulation of bone morphogenetic protein (BMP) signaling to AKI. Small m
Autor:
Reginald Valdez, Lin Fan, Yanqun Wang, Jiang Zhu, Sharon X. Wang, David J. Glass, Tea Shavlakadze, Joan Mannick, Weihua Zhou, Angelika Meyer, Oleg Iartchouk, Marc A. Egerman, Lloyd B. Klickstein, Bret Morin
Publikováno v:
The Journals of Gerontology: Series A. 73:845-852
Rapalogs, inhibitors of mTORC1 (mammalian target of rapamycin complex 1), increase life span and delay age-related phenotypes in many species. However, the molecular mechanisms have not been fully elucidated. We determined gene expression changes com
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory tract infections (RTIs) are a leading cause of hospitalization and death in people age ≥65 years. RTIs are caused by multiple viruses, most of which lack effective treatments. An immunotherapy that enhances pan-antiviral inna
Autor:
Peter McNamara, Jocelyn Zoll, Lianxing Zheng, Shelly Meeusen, Young Kim, Glenn C. Federe, Lihao Chen, Eloy D. Hernandez, John R. Walker, Dingjiu Bao, Lloyd B. Klickstein, William F. Dietrich, Paul Vincent Rucker, Valentina Molteni, Bin Fang, Reginald Valdez, Sean B. Joseph, Bo Liu, James Schmeits, Claire Dubois, Chianelli Donatella, Michael Badman, David C. Tully, Bryan Laffitte, Jie Xu
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 3, Iss 8, Pp 1085-1097 (2019)
Hepatology Communications, Vol 3, Iss 8, Pp 1085-1097 (2019)
Farnesoid X receptor (FXR) agonism is emerging as an important potential therapeutic mechanism of action for multiple chronic liver diseases. The bile acid‐derived FXR agonist obeticholic acid (OCA) has shown promise in a phase 2 study in patients